人乳头瘤病毒驱动的头颈癌的一级、二级和三级预防
人乳头瘤病毒(HPV)驱动的口咽癌在头颈癌中占比上升,可能在部分西方国家成为公共卫生问题。宫颈癌预防的成功鼓励将类似策略用于HPV驱动口咽癌,但存在重要局限,亟需开发针对该病的创新特异性策略。本文综述了HPV驱动口咽癌的一级、二级和三级预防并讨论未来研究方向。
要点
- HPV驱动口咽癌占比上升,部分西方国家未来数十年或成公共卫生问题。
- 预防性HPV疫苗和筛查项目已有效降低宫颈癌发病率,宫颈癌是HPV驱动恶性肿瘤的范例。
- 将宫颈癌预防策略用于HPV驱动口咽癌存在重要局限,亟需创新特异性策略。
核心结论
- 宫颈癌预防的成功鼓励开发类似策略预防HPV驱动口咽癌,但重要局限阻碍其应用,亟需针对该病的创新特异性策略。
研究设计与样本
- 本文为综述,提供HPV驱动口咽癌一级、二级和三级预防的概述并讨论未来研究方向。
主要发现
- HPV驱动口咽癌在头颈癌中占比增加,未来数十年可能在部分西方国家成为公共卫生问题。
- 在大多数正确应用预防性HPV疫苗和筛查项目的国家,宫颈癌发病率自20世纪60年代以来大幅下降。
- 将宫颈癌预防策略用于HPV驱动口咽癌面临重要局限。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human papillomavirus (HPV)-driven oropharyngeal cancers (OPCs) represent an increasing proportion of head and neck cancers that could become, in the next few decades, a public health problem in certain western countries. This significant epidemiological change strongly calls for preventive measures. Prophylactic HPV vaccination and screening programmes for early identification and treatment of premalignant lesions are currently being used to reduce the incidence of uterine cervical cancer, which is the paradigm of HPV-driven malignancy. These strategies have proven to be efficient as the incidence of cervical cancer has dramatically dropped since the 1960s in most countries where they are properly applied. The success of cervical cancer prevention encourages the development of similar approaches to prevent HPV-driven OPCs. However, a number of important limitations impede their application to HPV-driven OPCs, and the development of innovative and specific strategies dedicated to this disease are urgently needed. This article provides an overview on primary, secondary and tertiary prevention of HPV-driven OPC and discusses some directions for future research.
引用
- Mirghani H, Jung AC, Fakhry C, et al. Primary, secondary and tertiary prevention of human papillomavirus-driven head and neck cancers. Eur J Cancer. 2017. PMID: 28437708. doi:10.1016/j.ejca.2017.03.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。